IE 11 is not supported. For an optimal experience visit our site on another browser.

Chelsea Therapeutics to Present at 10th Annual Needham Healthcare Conference

CHARLOTTE, N.C., April 5, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 10th Annual Needham Healthcare Conference at 2:00 PM ET on Wednesday April 6, 2011 at the New York Palace Hotel in New York City.
/ Source: GlobeNewswire

CHARLOTTE, N.C., April 5, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 10th Annual Needham Healthcare Conference at 2:00 PM ET on Wednesday April 6, 2011 at the New York Palace Hotel in New York City.

Dr. Simon Pedder, Chelsea's president and chief executive officer, will provide a brief overview of the company's product pipeline, clinical development status and upcoming milestones.

Dr. Pedder's presentation will be webcast live and archived for 30 days on Chelsea's website, .

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, NORTHERA™ (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates droxidopa and CH-4051, reliance on collaborations and licenses, intellectual property risks, our need to raise additional operating capital in the future, our history of losses, competition, market acceptance for our products if any are approved for marketing, and reliance on key personnel including specifically Dr. Pedder.

CONTACT: Chelsea Therapeutics: Kathryn McNeil Investor/Media Relations 718-788-2856 mcneil@chelseatherapeutics.com